Close Menu

NEW YORK (GenomeWeb) – Rubicon Genomics today announced that it has extended a clinical supply agreement providing its TransPlex whole-genome RNA amplification technology to Agendia for use in its MammaPrint 70-Gene breast cancer recurrence assay.

In early 2012, Agendia first inked the deal to use Rubicon's technology to analyze formalin-fixed, paraffin-embedded (FFPE) breast cancer samples on its Symphony suite of diagnostics, which includes MammaPrint.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.